Semaglutide reduces risk of cardiovascular events in patients with type 2 diabetes, finds study
Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...
The American Journal of Managed Care20h
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...
MPR22h
Semaglutide Improves Walking Ability in T2D Patients With Peripheral Artery Disease
Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...